To maximize the drugability potential, we target approaches to improve clinical benefits based on reverse translational science and emerging biology of the tumor microenvironment.
(Reverse)Translational Science
Identification of patients' unmet needs, novel targets, pathways, and mechanisms.
Drug Discovery & Development
Validation of target, mechanism of action, and proof of concept, and development of novel engager with high potency and good safety profile.
Immunotherapy
Boosting of anti-tumor immunity to fight against cancer.
Direct engagement of myeloid cells with target cells.
Activation of killing mechanism (such as phagocytosis) by myeloid cells directed towards target cells.
Stimulation of myeloid cells to release minimal cytokines and chemokines known to reprogram and reset the immunosuppressive tumor microenvironment and enhance cytotoxic T cell function.
Cross presentation of tumor neoantigens and activation of tumor-specific T cells to support durable anti-tumor immune responses and immunological memory.
REDWOOD CITY, California and SHENZHEN, China – May 6, 2026 – LTZ Therapeutics, a clinical-stage, immunotherapy-focused biotechnology company, today announced the completion of an oversubscribed $38 million financing round to accelerate development of its Universal Myeloid Cell Engager (U-MCETM)-based immunotherapy pipeline, particularly its lead asset LTZ-301 targeting oncology and autoimmune diseases.
General Inquiries
info@ltztherapeutics.comBusiness Development
vivian.tian@ltztherapeutics.comRedwood City, USA
1100 Island Dr., Suite 103, Redwood City, CA, 94065Shenzhen, China
Room 3004, Building B, New Building of Research Institute of Tsinghua University in Shenzhen, Yuehai Sub-district, High-tech Zone Community, Gaoxin South 39th Road, Nanshan District, Shenzhen 518057@ 2026 LTZ Therapeutics Inc., All Rights Reserved.
Privacy Policy | Term of Use | Contact Us
为了更好的呈现效果，移动端请竖屏浏览
